Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.63 1.44 (1.6%) as of 4:30 Fri 4/19


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.70(B)
Last Volume: 1,778,607 Avg Vol: 1,398,026
52 Week Range: $76.22 - $99
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 638,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $60,375,372
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 57
End Date 2024-01-21 2023-10-20 2023-04-21 2022-04-21

   
Records found: 1356
  Page 4 of 55  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-29 5 GD $0.00 $0 I/I 7,011 36,184     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-29 4 S $81.10 $3,686,955 D/D (45,462) 99,200     -
   Baffi Robert EVP, Technical Operations   •       –      –    2014-10-29 4 OE $17.33 $1,533,721 D/D 45,462 144,662     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-24 4 AS $80.00 $160,000 I/I (2,000) 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-24 4 OE $12.99 $25,980 I/I 2,000 48,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-21 4 AS $75.00 $150,000 I/I (2,000) 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-10-21 4 OE $12.99 $25,980 I/I 2,000 48,195     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-09-19 4 AS $69.75 $1,223,136 D/D (17,536) 64,426     -
   Davis George Eric SVP, General Counsel   •       –      –    2014-09-19 4 OE $21.51 $377,199 D/D 17,536 81,962     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-09-03 4 S $69.70 $1,256 D/D (18) 68,733     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-09-02 4 S $69.83 $1,117,314 D/D (16,000) 68,676     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-09-02 4 OE $39.06 $624,960 D/D 16,000 84,676     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-08-20 4 AS $70.00 $350,000 I/I (5,000) 46,195     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-08-20 4 OE $12.99 $64,950 I/I 5,000 51,195     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-08-06 4 A $62.17 $870 D/D 14 68,751     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-08-05 4 AS $65.00 $650,000 D/D (10,000) 76,550     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-08-05 4 OE $21.51 $215,100 D/D 10,000 86,550     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-08-01 4 S $61.76 $137,652 D/D (2,229) 68,676     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-07-31 5 GD $0.00 $0 D/D 1,000 226,157     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2014-07-02 4 S $64.00 $142,656 D/D (2,229) 70,905     -
   Grey Michael G Director   –       •      –    2014-06-06 4 A $0.00 $0 D/D 2,100 25,150     -
   Mueller Brian VP, Corporate Controller   •       –      –    2014-06-04 4 A $0.00 $0 D/D 4,000 8,800     -
   Heron Elaine J Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 19,525     -
   Lewis Alan Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 2,100 21,400     -
   Slamon Dennis Director   –       •      –    2014-06-04 4 A $0.00 $0 D/D 525 5,225     -
  1356 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 55
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us